Investigators conducted a retrospective analysis at 19 trial sites where patients received at least one dose of the KEYNOTE-522 regimen for triple-negative breast cancer.

Even when diagnosed early, triple-negative breast cancer (TNBC) has a higher mortality rate compared with other breast cancer subtypes due to its aggressive nature. However, results from the ...

KEYTRUDA® (pembrolizumab) is the first and only immunotherapy-based regimen to show a statistically significant improvement in OS as pre-operative (neoadjuvant) treatment with chemotherapy and then as ...

Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor–Mutant ...

Presurgical Keytruda Plus Chemo, Postsurgical Keytruda Continued to Show Benefits in in patients with high-risk, early-stage triple-negative breast cancer. Patients with high-risk, early-stage ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 ...

PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant improvement in overall survival (OS), according to updated results from a large ...

Please provide your email address to receive an email when new articles are posted on . A study assessing the efficacy of pembrolizumab met a key secondary endpoint of extending OS, in combination ...

Please provide your email address to receive an email when new articles are posted on . Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended OS for ...

Pembrolizumab in early triple-negative breast cancer shows irAEs similar to KEYNOTE-522, with endocrinopathies and severe gastrointestinal effects being prevalent. The study involved a diverse patient ...